Eu Ivdd Eu Ivd General No Longer On The Market ๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands

CYSTIC FIBROSIS

NimaGen BV ยท ๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Devices (same UDI-DI)
1
Certificates
0
Countries
32
Notified Bodies
0

Basic Information

Primary DI
D-9017BF
Basic UDI-DI Code
B-9017BF
Reference
RC-CFHS096-I
Device Types
None provided
Regulation
Eu Ivdd
Classification
Eu Ivd General
Status
No Longer On The Market
Manufacturer
NimaGen BV

Additional Description

The intended purpose of this assay is NGS library preparation for Illuminaยฎ sequencing of human CFTR Hotspots; to aid in diagnosis of (the congenital predisposition to) cystic fibrosis by detecting sequence variants. The assay is designed for use with DNA extracted from peripheral blood. Specimens should have an absorbance ratio (260/280) of ~1.8, regardless of the extraction method used. The assay provides reagents for Multiplex Amplicon based NGS library preparation and is for professional use only. The kit is based on the patented Reverse Complement PCR technology, providing a safe, robust and simple workflow, combining multiplex amplification in a single reaction, decreasing risk for PCR contamination and sample swapping.

CND Nomenclature Codes

Code Description
W0106010101 CYSTIC FIBROSIS

Available In Countries

๐Ÿ‡ฆ๐Ÿ‡น Austria ๐Ÿ‡ง๐Ÿ‡ช Belgium ๐Ÿ‡ง๐Ÿ‡ฌ Bulgaria ๐Ÿ‡จ๐Ÿ‡พ Cyprus ๐Ÿ‡จ๐Ÿ‡ฟ Czechia ๐Ÿ‡ฉ๐Ÿ‡ช Germany ๐Ÿ‡ฉ๐Ÿ‡ฐ Denmark ๐Ÿ‡ช๐Ÿ‡ช Estonia ๐Ÿ‡ฌ๐Ÿ‡ท Greece ๐Ÿ‡ช๐Ÿ‡ธ Spain ๐Ÿ‡ซ๐Ÿ‡ฎ Finland ๐Ÿ‡ซ๐Ÿ‡ท France ๐Ÿ‡ญ๐Ÿ‡ท Croatia ๐Ÿ‡ญ๐Ÿ‡บ Hungary ๐Ÿ‡ฎ๐Ÿ‡ช Ireland ๐Ÿ‡ฎ๐Ÿ‡ธ Iceland ๐Ÿ‡ฎ๐Ÿ‡น Italy ๐Ÿ‡ฑ๐Ÿ‡ฎ Liechtenstein ๐Ÿ‡ฑ๐Ÿ‡น Lithuania ๐Ÿ‡ฑ๐Ÿ‡บ Luxembourg ๐Ÿ‡ฑ๐Ÿ‡ป Latvia ๐Ÿ‡ฒ๐Ÿ‡น Malta ๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands ๐Ÿ‡ณ๐Ÿ‡ด Norway ๐Ÿ‡ต๐Ÿ‡ฑ Poland ๐Ÿ‡ต๐Ÿ‡น Portugal ๐Ÿ‡ท๐Ÿ‡ด Romania ๐Ÿ‡ธ๐Ÿ‡ช Sweden ๐Ÿ‡ธ๐Ÿ‡ฎ Slovenia ๐Ÿ‡ธ๐Ÿ‡ฐ Slovakia ๐Ÿ‡น๐Ÿ‡ท Tรผrkiye ๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom

Similar Devices

Other on-the-market devices with the same classification (Eu Ivd General) and regulation (EU IVDD).

View all